We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Microsoft, Broadcom, Eli Lilly, Intuitive Surgical and MetLife
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 23, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corporation (MSFT - Free Report) , Broadcom Inc. (AVGO - Free Report) , Eli Lilly and Company(LLY - Free Report) ), Intuitive Surgical, Inc. (ISRG - Free Report) and MetLife, Inc. (MET - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Microsoft, Broadcom and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT - Free Report) , Broadcom Inc. (AVGO - Free Report) and Eli Lilly and Co. (LLY - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Microsoft have outperformed the S&P 500 over the past year (+49.3% vs. +28.3%). The Zacks analyst believes that Microsoft has been benefiting from strength in its Azure cloud platform as well as the accelerating global digital transformation.
Teams’ user growth has been steadily gaining from the continuation of remote work and an increased adoption of hybrid work model. Solid uptake of new Xbox consoles has been aiding the gaming segment performance. Microsoft, however, expects Surface revenues to decline in fiscal second quarter due to supply chain disruptions. Costs associated with Azure enhancements and stiff competition in the cloud space are also likely to dent margins.
Broadcom shares have gained +51.9% in the year to date period against the Zacks Electronics - Semiconductors industry’s gain of +43.8%. The Zacks analyst believes that Broadcom has been gaining from continued strength across both Semiconductor solutions and Infrastructure software verticals.
In fourth-quarter fiscal 2021, Semiconductor revenues benefited from higher demand for wireless solutions and continued momentum in networking and broadband solutions. Synergies from acquisitions of CA and Symantec’s enterprise security business aided results. An upbeat first quarter guidance on strong uptick in broadband, networking and wireless revenues is encouraging. Increasing competition and high debt levels, however, remain concerning.
Shares of Eli Lilly have gained +22.8% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +12.4%. The Zacks analyst believes that Lilly’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, etc.
Lilly recently submitted regulatory applications for tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both the candidates have multibillion dollar sales potential. It is also regularly adding promising new pipeline assets through business development deals. Generic competition for several drugs, rising pricing pressure in the United States (mainly on key drug Trulicity) remain as some top-line headwinds, though.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Microsoft, Broadcom, Eli Lilly, Intuitive Surgical and MetLife
For Immediate Release
Chicago, IL – December 23, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corporation (MSFT - Free Report) , Broadcom Inc. (AVGO - Free Report) , Eli Lilly and Company(LLY - Free Report) ), Intuitive Surgical, Inc. (ISRG - Free Report) and MetLife, Inc. (MET - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Microsoft, Broadcom and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT - Free Report) , Broadcom Inc. (AVGO - Free Report) and Eli Lilly and Co. (LLY - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Microsoft have outperformed the S&P 500 over the past year (+49.3% vs. +28.3%). The Zacks analyst believes that Microsoft has been benefiting from strength in its Azure cloud platform as well as the accelerating global digital transformation.
Teams’ user growth has been steadily gaining from the continuation of remote work and an increased adoption of hybrid work model. Solid uptake of new Xbox consoles has been aiding the gaming segment performance. Microsoft, however, expects Surface revenues to decline in fiscal second quarter due to supply chain disruptions. Costs associated with Azure enhancements and stiff competition in the cloud space are also likely to dent margins.
(You can read the full research report on Microsoft here >>>)
Broadcom shares have gained +51.9% in the year to date period against the Zacks Electronics - Semiconductors industry’s gain of +43.8%. The Zacks analyst believes that Broadcom has been gaining from continued strength across both Semiconductor solutions and Infrastructure software verticals.
In fourth-quarter fiscal 2021, Semiconductor revenues benefited from higher demand for wireless solutions and continued momentum in networking and broadband solutions. Synergies from acquisitions of CA and Symantec’s enterprise security business aided results. An upbeat first quarter guidance on strong uptick in broadband, networking and wireless revenues is encouraging. Increasing competition and high debt levels, however, remain concerning.
(You can read the full research report on Broadcom here >>>)
Shares of Eli Lilly have gained +22.8% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +12.4%. The Zacks analyst believes that Lilly’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, etc.
Lilly recently submitted regulatory applications for tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both the candidates have multibillion dollar sales potential. It is also regularly adding promising new pipeline assets through business development deals. Generic competition for several drugs, rising pricing pressure in the United States (mainly on key drug Trulicity) remain as some top-line headwinds, though.
(You can read the full research report on Eli Lilly here >>>)
Other noteworthy reports we are featuring today include Intuitive Surgical and MetLife.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.